ATRX represses alternative lengthening of telomeres
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
// Christine E. Napier 1 , Lily I. Huschtscha 1 , Adam Harvey 2 , Kylie Bower 1 , Jane R. Noble 1 , Eric A. Hendrickson 2 and Roger R. Reddel 1,2 1 Cancer Research Unit, Children’s Medical Research Institute, The University of Sydney, Westmead, NSW, Australia 2 Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota Medical School, Minneapolis, MN, USA Correspondence to: Roger R. Reddel , email: // Keywords : ATRX, ALT, telomere, immortalization Received : December 18, 2014 Accepted : March 20, 2015 Published : April 15, 2015 Abstract The unlimited proliferation of cancer cells requires a mechanism to prevent telomere shortening. Alternative Lengthening of Telomeres (ALT) is an homologous recombination-mediated mechanism of telomere elongation used in tumors, including osteosarcomas, soft tissue sarcoma subtypes, and glial brain tumors. Mutations in the ATRX/DAXX chromatin remodeling complex have been reported in tumors and cell lines that use the ALT mechanism, suggesting that ATRX may be an ALT repressor. We show here that knockout or knockdown of ATRX in mortal cells or immortal telomerase-positive cells is insufficient to activate ALT. Notably, however, in SV40-transformed mortal fibroblasts ATRX loss results in either a significant increase in the proportion of cell lines activating ALT (instead of telomerase) or in a significant decrease in the time prior to ALT activation. These data indicate that loss of ATRX function cooperates with one or more as-yet unidentified genetic or epigenetic alterations to activate ALT. Moreover, transient ATRX expression in ALT-positive/ATRX-negative cells represses ALT activity. These data provide the first direct, functional evidence that ATRX represses ALT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750 · cited 1×
“Telomeres are repetitive DNA structures located at the ends of chromosomes that shorten with each cell division [1].”
BackgroundIdentification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400 · cited 1×
“There are two mechanisms currently known to maintain telomere length in human cells: the reverse transcriptase enzyme telomerase and the recombination-mediated DNA synthesis mechanism called Alternative Lengthening of Telomeres (ALT) [2, 3].”
BackgroundEfficient genome editing in zebrafish using a CRISPR-Cas system
Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., Peterson, R. T., Yeh, J.-R. J., & Joung, J. K. (2013) · Nature Biotechnology · doi:10.1038/nbt.2501 · Cited by 2,937 · cited 1×
“The ATRX cDNA was screened by ZiFiT to determine a CRISPR target in exon 9 of ATRX [37].”
MethodDriver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631 · cited 1×
“More recently, it was found that inactivating mutations in one or other of the genes encoding the ATRX/DAXX chromatin remodeling complex, most commonly ATRX, are very common in ALT-positive tumors and cell lines [6-10].”
BackgroundCounter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096 · cited 1×
“After a finite number of additional cell divisions, however, the cells cease proliferation and the culture enters crisis, until a rare cell (approximately 1 in 107 fibroblasts and 1 in 105 epithelial cells) escapes crisis through spontaneous activation of a telomere lengthening mechanism (TLM), and the cell culture be…”
BackgroundDynamic Imaging of Genomic Loci in Living Human Cells by an Optimized CRISPR/Cas System
Chen, B., Gilbert, L. A., Cimini, B. A., Schnitzbauer, J., Zhang, W., Li, G.-W., Park, J., Blackburn, E. H., Weissman, J. S., Qi, L. S., et al. (2013) · Cell · doi:10.1016/j.cell.2013.12.001 · Cited by 1,963 · cited 3×
“We also showed that successful knockout of ATRX using CRISPR/Cas9 technology or rAAV in epithelialderived HCT116 colon carcinoma cells did not affect telomerase expression nor activate ALT.”
InfluentialJiao, Y., Shi, C., Edil, B. H., de Wilde, R. F., Klimstra, D. S., Maitra, A., Schulick, R. D., Tang, L. H., Wolfgang, C. L., Choti, M. A., et al. (2011) · Science · doi:10.1126/science.1200609 · Cited by 1,717 · cited 1×
“ATRX was sequenced using described primers and conditions [42].”
MethodTelomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279 · cited 2×
“Somatic cell hybridization analyses showed that ALT activation occurs through loss of one or more repressor molecules that are present in normal somatic cells and in telomerase positive cells [3, 5].”
BackgroundSelf-citationAltered Telomeres in Tumors with ATRX and DAXX Mutations
Heaphy, C. M., de Wilde, R. F., Jiao, Y., Klein, A. P., Edil, B. H., Shi, C., Bettegowda, C., Rodriguez, F. J., Eberhart, C. G., Hebbar, S., et al. (2011) · Science · doi:10.1126/science.1207313 · Cited by 1,083 · cited 3×
“Mutations in members of the ATRX/DAXX chromatin remodeling complex have been implicated in the ALT mechanism, in both ALT-positive cell lines and tumor samples [6, 7, 11, 23].”
BackgroundYeager, T. R., Neumann, A. A., Englezou, A., Huschtscha, L. I., Noble, J. R., & Reddel, R. R. (1999) · PubMed · Cited by 845
Self-citation
Cited by
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
Jafri, M. A., Ansari, S. A., Alqahtani, M. H., & Shay, J. W. (2016) · Genome Medicine · doi:10.1186/s13073-016-0324-x · Cited by 716
“ATRX acts as a suppressor of ALT in normal cells and mutations in ATRX and DAXX contribute to activation of ALT [28, 91].”
BackgroundTargeting telomerase for cancer therapy
Guterres, A. N., & Villanueva, J. (2020) · Oncogene · doi:10.1038/s41388-020-01405-w · Cited by 256
Role of the cGAS–STING pathway in cancer development and oncotherapeutic approaches
Khoo, L. T., & Chen, L. (2018) · The EMBO Reports · doi:10.15252/embr.201846935 · Cited by 204
Molecular mechanisms of activity and derepression of alternative lengthening of telomeres
Pickett, H. A., & Reddel, R. R. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3106 · Cited by 203
Self-citationConklin, Q. A., King, B. G., Zanesco, A. P., Lin, J., Hamidi, A. B., Pokorny, J. J., Álvarez-López, M. J., Cosín-Tomás, M., Huang, C., Kaliman, P., et al. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.03.003 · Cited by 66
Metadata
- Authors
- Napier, C. E., Huschtscha, L. I., Harvey, A., Bower, K., Noble, J. R., Hendrickson, E. A., & Reddel, R. R.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-04-15
- Volume
- 6
- Issue
- 18
- Pages
- 16543-16558
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1583495800
- Cited by
- 181
- References
- 43
- FWCI
- 10.33
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.